V1 sact_regimen
730,471 rows · 12 columns
| MERGED_REGIMEN_ID | MERGED_TUMOUR_ID | HEIGHT_AT_START_OF_REGIMEN | WEIGHT_AT_START_OF_REGIMEN | INTENT_OF_TREATMENT | DATE_DECISION_TO_TREAT | START_DATE_OF_REGIMEN | MAPPED_REGIMEN | CLINICAL_TRIAL | CHEMO_RADIATION | MERGED_PATIENT_ID | BENCHMARK_GROUP |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 220020680 | 220017654 | 1.72 | 81 | Curative (C) | 2017-11-21 | 2017-11-21 | ALEMTUZUMAB + FLUDARABINE + MELPHALAN | 02 | N | 220028304 | ALEMTUZUMAB + FLUDARABINE + MELPHALAN |
| 220020681 | 220007343 | 1.82 | null | Curative (C) | 2015-07-12 | 2015-07-12 | Dasatinib | N | N | 220028308 | DASATINIB |
| 220020682 | 220007347 | 1.66 | 63.5 | Disease modification (D) | 2013-04-27 | 2013-12-07 | Dasatinib | 01 | N | 220028341 | DASATINIB |
| 220020683 | 220007350 | 1.7 | null | null | 2015-10-29 | 2015-10-29 | Dasatinib | 99 | N | 220028355 | DASATINIB |
| 220020684 | 220017661 | 1.71 | 0 | Curative (C) | 2019-06-16 | 2019-06-17 | Rituximab | N | N | 220028388 | RITUXIMAB |
| 220020685 | 220014056 | 0 | 44.7 | Disease modification (D) | 2016-02-02 | 2016-02-02 | ALEMTUZUMAB + FLUDARABINE + MELPHALAN | 2 | N | 220028395 | ALEMTUZUMAB + FLUDARABINE + MELPHALAN |
| 220020686 | 220007362 | 1.78 | 108 | Curative (C) | 2014-10-24 | 2014-10-24 | ALEMTUZUMAB + FLUDARABINE + MELPHALAN | N | N | 220028396 | ALEMTUZUMAB + FLUDARABINE + MELPHALAN |
| 220020687 | 220021883 | 1.74 | 90 | Curative (C) | null | 2017-03-20 | AML18 PILOT TRIAL | null | N | 220028429 | PILOT TRIAL |
| 220020688 | 220007379 | null | 77.7 | Disease modification (D) | 2013-11-25 | 2014-02-13 | Alemtuz+Fludara+Melphalan RIC MUD | 02 | N | 220028490 | ALEMTUZUMAB + FLUDARABINE + MELPHALAN |
| 220020689 | 220007385 | null | 59.4 | Curative (C) | 2015-03-05 | 2015-04-05 | ALEMTUZUMAB + FLUDARABINE + MELPHALAN | null | N | 220028504 | ALEMTUZUMAB + FLUDARABINE + MELPHALAN |
| 220020690 | 220007390 | 1.8 | 90 | Curative (C) | 2016-04-27 | 2016-04-27 | Rituximab | N | N | 220028517 | RITUXIMAB |
| 220020691 | 220007398 | 1.63 | 87 | Curative (C) | 2017-04-21 | 2017-06-10 | AML18 PILOT TRIAL | Y | N | 220028542 | PILOT TRIAL |
| 220020692 | 220007419 | 1.81 | 83.7 | Disease modification (D) | 2017-12-06 | 2017-12-06 | Rituximab | N | N | 220028662 | RITUXIMAB |
| 220020693 | 220014088 | 1.67 | 50.4 | null | 2016-08-05 | 2016-08-06 | ALEMTUZUMAB + FLUDARABINE + MELPHALAN | N | N | 220028681 | ALEMTUZUMAB + FLUDARABINE + MELPHALAN |
| 220020694 | 220007425 | 1.8 | null | Curative (C) | 2013-11-24 | 2014-10-14 | Dasatinib | N | N | 220028684 | DASATINIB |
| 220020695 | 220007431 | 1.49 | 0 | Curative (C) | null | 2014-11-12 | AML18 PILOT TRIAL | 01 | null | 220028709 | PILOT TRIAL |
| 220020696 | 220007443 | 1.79 | 72 | Curative (C) | 2017-08-28 | 2017-09-01 | AML 18 TRIAL | 01 | N | 220028763 | AML18 TRIAL |
| 220020697 | 220021885 | 1.67 | 78.4 | Disease modification (D) | 2014-10-09 | 2014-10-16 | ALEMTUZUMAB + FLUDARABINE + MELPHALAN | 2 | N | 220028778 | ALEMTUZUMAB + FLUDARABINE + MELPHALAN |
| 220020698 | 220007452 | null | null | Disease modification (D) | 2013-07-18 | 2013-08-25 | Rituximab | N | N | 220028801 | RITUXIMAB |
| 220020699 | 220007458 | 1.72 | 89.4 | Curative (C) | 2018-05-29 | 2018-05-29 | AML 18 Pilot Trial | N | Y | 220028807 | PILOT TRIAL |
| 220020700 | 220014106 | 1.56 | 62.9 | Palliative (P) | 2018-02-07 | 2018-04-18 | AML 18 TRIAL | 01 | N | 220028812 | AML18 TRIAL |
| 220020701 | 220007472 | 1.65 | 95.2 | null | 2016-03-25 | 2016-03-25 | Rituximab | 99 | N | 220028868 | RITUXIMAB |
| 220020702 | 220007479 | 1.78 | 67.2 | Curative (C) | 2016-01-05 | 2016-06-17 | AML18 PILOT TRIAL | N | N | 220028892 | PILOT TRIAL |
| 220020703 | 220007483 | 1.5 | 0 | Disease modification (D) | 2016-06-10 | 2016-06-14 | Dasatinib | N | N | 220028901 | DASATINIB |
| 220020705 | 220007510 | null | 90 | Curative (C) | 2015-02-23 | 2015-02-23 | Alemtuz+Fludara+Melphalan RIC MUD | 02 | N | 220028990 | ALEMTUZUMAB + FLUDARABINE + MELPHALAN |
| 220020706 | 220007516 | 1.52 | 81 | Curative (C) | 2015-05-08 | 2015-06-10 | AML18 PILOT TRIAL | 02 | N | 220028997 | PILOT TRIAL |
| 220020707 | 220007517 | 1.6 | 44.3 | Curative (C) | 2018-02-07 | 2018-03-25 | AML 18 TRIAL | Y | N | 220028999 | AML18 TRIAL |
| 220020708 | 220007529 | null | null | null | 2018-06-02 | 2018-06-05 | Rituximab | N | null | 220029043 | RITUXIMAB |
| 220020710 | 220007548 | 1.78 | 72.7 | Curative (C) | 2018-04-21 | 2018-04-26 | AML18 PILOT TRIAL | N | N | 220029118 | PILOT TRIAL |
| 220020711 | 220007551 | 1.79 | 80.7 | Curative (C) | 2014-07-19 | 2014-09-04 | AML 18 TRIAL | Y | N | 220029122 | AML18 TRIAL |
| 220020713 | 220007555 | 1.61 | 57.2 | Curative (C) | 2015-12-24 | 2016-01-10 | Alemtuz+Fludara+Melphalan RIC MUD | N | N | 220029134 | ALEMTUZUMAB + FLUDARABINE + MELPHALAN |
| 220020715 | 220007579 | 0 | 80.9 | Curative (C) | 2019-07-15 | 2019-10-18 | Alemtuz+Fludara+Melphalan RIC MUD | N | N | 220029242 | ALEMTUZUMAB + FLUDARABINE + MELPHALAN |
| 220020716 | 220007583 | 1.58 | 71.9 | null | 2017-08-17 | 2017-08-20 | AML 18 TRIAL | null | N | 220029268 | AML18 TRIAL |
| 220020717 | 220007584 | 1.74 | 65 | Curative (C) | 2016-01-06 | 2016-01-06 | ATG + Busulfan + Fludarabine | 02 | N | 220029273 | ATG + BUSULFAN + FLUDARABINE |
| 220020718 | 220007588 | 1.65 | 84.6 | Curative (C) | null | 2018-06-12 | CYCLOPHOSPHAMIDE + FLUDARABINE | null | N | 220029292 | CYCLOPHOSPHAMIDE + FLUDARABINE |
| 220020719 | 220007595 | 1.7 | 68.2 | Curative (C) | 2019-02-27 | 2019-03-02 | CYCLOPHOSPHAMIDE + FLUDARABINE | N | N | 220029327 | CYCLOPHOSPHAMIDE + FLUDARABINE |
| 220020721 | 220014197 | 1.73 | 147 | Curative (C) | 2014-07-04 | 2014-07-11 | AML16 DA 2+5 | null | N | 220029445 | AML16 TRIAL |
| 220020722 | 220007636 | 1.43 | 68.8 | Curative (C) | null | 2017-04-02 | BOSUTINIB | Y | null | 220029467 | BOSUTINIB |
| 220020723 | 220007639 | 1.6 | 79.4 | Curative (C) | 2015-10-12 | 2015-11-20 | RUXOLITINIB | N | N | 220029470 | RUXOLITINIB |
| 220020724 | 220007652 | 1.55 | 60 | Palliative (P) | 2014-01-27 | 2014-02-03 | RUXOLITINIB | N | N | 220029514 | RUXOLITINIB |
| 220020725 | 220019739 | 1.68 | 61.2 | Curative (C) | 2016-08-06 | 2016-08-06 | FLAG | N | N | 220029559 | FLAG |
| 220020726 | 220017759 | null | 60 | Curative (C) | 2014-07-28 | 2014-07-31 | Cyclophosphamide TBI Allograft | N | null | 220029586 | CYCLOPHOSPHAMIDE |
| 220020727 | 220007667 | 1.63 | 14 | Curative (C) | 2016-11-19 | 2016-11-19 | Idarubicin+Tretinoin Spanish Crse4 | null | null | 220029599 | IDARUBICIN + TRETINOIN |
| 220020728 | 220007672 | null | 70.2 | Curative (C) | 2017-11-16 | 2017-11-21 | BOSUTINIB | 99 | null | 220029606 | BOSUTINIB |
| 220020729 | 220007673 | null | 70.8 | Curative (C) | 2018-01-03 | 2018-01-23 | Idarubicin+Tretinoin Spanish Crse4 | 2 | null | 220029608 | IDARUBICIN + TRETINOIN |
| 220020730 | 220007680 | null | 60.5 | Curative (C) | null | 2018-07-17 | RUXOLITINIB | N | N | 220029630 | RUXOLITINIB |
| 220020731 | 220007691 | 0 | null | Palliative (P) | 2013-11-27 | 2013-12-02 | Triple Intrathecal | 2 | N | 220029667 | TRIPLE INTRATHECAL |
| 220020732 | 220007693 | 1.58 | 80.9 | Curative (C) | null | 2015-01-10 | CYCLOPHOSPHAMIDE | 02 | N | 220029672 | CYCLOPHOSPHAMIDE |
| 220020733 | 220007706 | null | 54.4 | Disease modification (D) | 2016-11-21 | 2017-04-06 | IDARUBICIN + TRETINOIN | 99 | N | 220029704 | IDARUBICIN + TRETINOIN |
| 220020734 | 220007716 | null | 60.3 | Curative (C) | 2017-11-25 | 2018-01-13 | AML16 DA 3+10 | 99 | null | 220029746 | AML16 TRIAL |